A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer

    loading  Checking for direct PDF access through Ovid



Previous studies investigating the association between BRAF mutations and nonsmall cell lung cancer (NSCLC) remain controversial. To address the issue, we performed an updated meta-analysis of related articles.


We conducted a comprehensive literature search in the electronic databases including ISI Science Citation Index, EMBASE, PubMed, and CNKI (up to January 2016). The odds ratios (ORs) and 95% confidence interval (CI) were assessed based on random-effects or fixed-effects models according to the heterogeneity of eligible studies.


A total of 16 studies enrolled 11,711 patients with NSCLC were involved in the meta-analysis. The overall BRAF mutation rate was 2.6% (303/11,711). There was a significant association between BRAF mutations and adenocarcinomas (ADCs) in NSCLC compared with non-ADCs (OR = 3.96, 95% CI = 2.13–7.34, P < 0.0001). No significant difference was observed in smoking and stage in patients with BRAF mutations. However, a significant difference of BRAF mutation rate was observed between women and men (OR = 0.72, 95% CI = 0.55–0.95, P = 0.02). In addition, the BRAFV600E mutations were more frequent in women (OR = 0.45, 95% CI = 0.26–0.77, P = 0.004) and never smokers (OR = 0.12, 95% CI = 0.05–0.29, P < 0.00001).


BRAF mutations in ADCS and female significantly increased the risk of NSCLC compared to non-ADCS and male, respectively. BRAFV600E mutation in NSCLC patients was significantly associated with female and nonsmokers.

Related Topics

    loading  Loading Related Articles